Roche’s giredestrant miss refines treatment settings for oral SERDs

The selective oral estrogen receptor degrader that’s been charting the path for development in early-line breast cancer settings has faced its first Phase III setback, and it’s possible the results could read through to other oral SERDs in first-line trials.

Giredestrant from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) did not meet the primary progression-free survival endpoint in the Phase III persevERA trial, which tested the candidate in combination with CDK4/6 inhibitor palbociclib as first-line treatment for HER2-negative, estrogen receptor-positive breast cancer...